Nirsevimab for RSV Reduces Infant Hospitalizations by 82% in Real-World Study
In a new real-world study, Sanofi and AstraZeneca’s nirsevimab-alip (Beyfortus) demonstrated high efficacy against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD).
Moderna Investigational Influenza Vaccine Meets Safety, Efficacy Endpoints Across Phase 3 Trials
Moderna reported at its annual R&D day that its flu vaccine has met primary phase 3 endpoints and that phase 1/2 data show higher HIA titers vs Fluzone HD.
With New COVID-19 Variant on the Rise, Vaccine Manufacturers Test Fall 2023 Monovalent Shots
Eris, or EG5, is of Omicron lineage and accounts for ~17% of reported COVID-19 cases; mRNA vaccine producers are confident in the new shots to protect against it.
Evusheld EUA Withdrawn, FDA Recommends Other Therapies
The FDA wants clinicians to avoid using the neutralizing antibody as it appears to be less effective against newer circulating strains of the SARS-CoV-2 virus.
Pfizer-BioNTech Request EUA for Bivalent COVID-19 Vaccine for Fall
Pfizer-BioNTech filed with the FDA for emergency use authorization of a 30-mcg dose of an Omicron BA.4.BA.5-adapted vaccine for those aged ≥12 years.
